An interventional study of Vigamox - administration in spray form and Vigamox eye drops in Cataract, sponsored by Advanced Ophthalmic Pharma. Completed at 1 site in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2012-01-19.
Sponsored by Advanced Ophthalmic Pharma · Not applicable and Interventional
The study compares the amounts of Vigamox absorbed when administered as eye drops or in a spray form. Both administrations will be prior to patients undergoing elective cataract surgery and the aqueous samples will be analyzed by a laboratory in a masked fashion. The hypothesis is that there will be no difference between the 2 modes of administration.
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's planned enrollment of 16 is below the median of 80 across 1,155 interventional studies indexed under Cataract.
Browse Cataract studies →Advanced Ophthalmic Pharma is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Vigamox delivered as spray
Drug: Vigamox - administration in spray form
Patients will receive the commercially available Vigamox drops
Drug: Vigamox eye drops
Vigamox will be administered in a spray form
Vigamox eye drops
Bioequivalency between the 2 ways of administration
Time frame: 4 months
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Advanced Ophthalmic Pharma